{"title":"Dermatologische Brennpunkte für den Hausarzt.","authors":"Reinhard Dummer","doi":"10.23785/TU.2025.04.001","DOIUrl":"10.23785/TU.2025.04.001","url":null,"abstract":"<p><strong>Introduction: </strong></p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 4","pages":"105"},"PeriodicalIF":0.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Claudia Lang, Matthias Möhrenschlager, Peter Schmid-Grendelmeier
{"title":"[Contemporary management of atopic dermatitis: from basic skincare to targeted systemic therapies].","authors":"Claudia Lang, Matthias Möhrenschlager, Peter Schmid-Grendelmeier","doi":"10.23785/TU.2025.04.002","DOIUrl":"https://doi.org/10.23785/TU.2025.04.002","url":null,"abstract":"<p><strong>Introduction: </strong>Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus, eczema, and impaired skin barrier. In recent years we have seen significant advances in the treatment of AD, with the introduction of new topical and systemic therapies. In addition to basic therapy and classic topical steroids and calcineurin inhibitors other topical substances and for severe forms systemic biologics and Janus kinase inhibitors are now available. Therapy selection is individualized, level-based considering disease severity, and regarding comorbidities and patient preferences. This article provides an up-to-date overview of evidence-based therapeutic options, discusses their efficacy and safety, and offers an outlook on future developments.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 4","pages":"106-110"},"PeriodicalIF":0.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[The Spitz nevus is not a melanoma in childhood].","authors":"Mario Teufer, Reinhard Dummer","doi":"10.23785/TU.2025.04.006","DOIUrl":"https://doi.org/10.23785/TU.2025.04.006","url":null,"abstract":"<p><strong>Introduction: </strong>The classic Spitz nevus is a benign, biologically stable melanocytic lesion in children and should not be equated with melanoma or its precursors. In contrast, Spitz tumors as a group represent a heterogeneous spectrum of melanocytic neoplasms, ranging from benign nevi to intermediate lesions with uncertain biological behavior and, rarely, malignant Spitz melanomas. Accurate classification relies on an integrative assessment of clinical, histological, and immunohistochemical features, complemented by molecular analyses in selected cases. Age-related risk stratification, growth behavior, architectural symmetry, and markers of maturation and proliferation are key determinants. The primary objective is not semantic categorization but rather a precise estimation of biological potential. This diagnostic approach helps to avoid overtreatment of stable lesions while enabling early detection of rare progressive cases. A structured, age-appropriate, and interdisciplinary diagnostic strategy is essential for informed and responsible clinical decision-making.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 4","pages":"124-129"},"PeriodicalIF":0.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[What's new about cutaneous T-cell lymphoma?]","authors":"Andrea Roggo","doi":"10.23785/TU.2025.04.004","DOIUrl":"https://doi.org/10.23785/TU.2025.04.004","url":null,"abstract":"<p><strong>Introduction: </strong>Cutaneous T-cell lymphomas (CTCL) are rare skin-predominant lymphomas, with Mycosis fungoides being the most common subtype. In Europe, the incidence is about 0.3 per 100 000 patient years. The majority of patients are suffering from limited disease with a 5-year survival of 90 %. Clinically, skin lesions can mimic eczema or psoriasis, leading to delayed diagnosis. CTCL diagnosis requires a combination of clinical examination, skin biopsy with histopathological analysis and blood tests to assess systemic involvement. CTCL treatment is stage-dependent. Depending on the stage of the disease, local or systemic therapies can be used. Individually optimised combinations are common. Novel targeted therapies such as brentuximab vedotin and mogamulizumab have expanded the treatment landscape, offering more effective and personalized options. Allogeneic stem cell transplantation is the only curative approach. In CTCL, quality of life is often impaired due to chronic itching, fatigue, and stigmatizing skin lesions. Psychodermatologic care plays a key role in comprehensive patient support.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 4","pages":"117-120"},"PeriodicalIF":0.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[The importance of clinical-pathological correlation in dermatohistopathology].","authors":"Beda Mühleisen","doi":"10.23785/TU.2025.04.005","DOIUrl":"10.23785/TU.2025.04.005","url":null,"abstract":"<p><strong>Introduction: </strong>Correct and precise dermatohistopathologic diagnosis requires excellent histopathologic knowledge on the one hand, and on the other hand often a close correlation between clinical findings and histopathologic results. Clinicopathologic correlation (CPC) is essential to further improve the quality of histopathologic diagnosis and reduce the risk of misdiagnosis. This article describes the importance of CPC using examples of typical dermatoses that would be difficult to diagnose histologically alone and highlights the forms and chances of CPC.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 4","pages":"121-123"},"PeriodicalIF":0.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Tattoo ink between beauty and risk: regulation in Switzerland, the EU and the USA].","authors":"Thomas D Szucs","doi":"10.23785/TU.2025.04.009","DOIUrl":"10.23785/TU.2025.04.009","url":null,"abstract":"<p><strong>Introduction: </strong>The growing popularity of tattoos highlights the importance of careful regulation of tattoo inks to minimise health risks. In Switzerland, tattoo inks are subject to strict legal requirements based on food legislation, which are designed to ensure that they are sterile and harmless. The European Union has significantly tightened restrictions on substances in tattoo inks through Regulation (EU) 2020/2081 in order to increase safety. In contrast, the USA regulate tattoo inks under the supervision of the Food and Drug Administration (FDA), but do not have specific pre-market controls for tattoo ink products. This comparison highlights different regulatory approaches in Switzerland, the EU and the USA and underlines the need for more harmonised global regulation to protect consumer health.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 4","pages":"138-140"},"PeriodicalIF":0.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Cutaneous reactions to drugs].","authors":"Ines Lederbogen, Barbara Meier-Schiesser","doi":"10.23785/TU.2025.04.003","DOIUrl":"https://doi.org/10.23785/TU.2025.04.003","url":null,"abstract":"<p><strong>Introduction: </strong>Adverse drug reactions (ADRs) are a major global health problem with high morbidity and mortality rates. They are divided into two main types: the more common type A reactions, which are dose-dependent and usually predictable, and the rarer type B reactions, which occur independently of the dose and require an individual predisposition on the part of the patient and often pose a particular challenge in everyday clinical practice. The majority of cutaneous adverse drug reactions (ADRs) are uncomplicated. The most common are maculopapular exanthema, which typically represent a type IV hypersensitivity reaction. Serious cutaneous ADRs, on the other hand, are rare but can be potentially life-threatening. Skin changes associated with immune checkpoint inhibitors and other immunotherapies represent a separate entity within cutaneous drug reactions. Immune-related adverse events (irAE) are common in immunotherapy and are considered in many cases to be a correlate of a positive therapeutic response.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 4","pages":"111-116"},"PeriodicalIF":0.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145201560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Secondary Headaches].","authors":"Laura Weichsel, Christoph Schankin","doi":"10.23785/TU.2025.03.006","DOIUrl":"https://doi.org/10.23785/TU.2025.03.006","url":null,"abstract":"<p><strong>Introduction: </strong>In clinical practice, correctly diagnosing headaches can be challenging due to the many differential diagnoses. It is particularly important to differentiate between the more common primary headache types, where the headache itself is the main condition, and secondary headaches, which may have potentially lifethreatening causes. The diagnostic approach initially focuses on identifying secondary headaches.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 3","pages":"94-99"},"PeriodicalIF":0.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Polyneuropathies - a practical overview].","authors":"Marisa Blanquet, Andrea M Humm","doi":"10.23785/TU.2025.03.004","DOIUrl":"https://doi.org/10.23785/TU.2025.03.004","url":null,"abstract":"<p><strong>Introduction: </strong>Polyneuropathies are common, can have very different clinical presentations and numerous causes. This article is intended to provide a practice-oriented overview of possible symptoms, the most important causes and a targeted, step-by-step diagnostic approach. Based on red flags, patients should be identified who urgently require a timely specialist assessment. The most important treatment approaches should be briefly explained.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 3","pages":"82-87"},"PeriodicalIF":0.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sebastian Kaufmann, Hakan Sarikaya, Moritz Kielkopf
{"title":"[Leading neurological symptoms of stroke].","authors":"Sebastian Kaufmann, Hakan Sarikaya, Moritz Kielkopf","doi":"10.23785/TU.2025.03.007","DOIUrl":"https://doi.org/10.23785/TU.2025.03.007","url":null,"abstract":"<p><strong>Introduction: </strong>Stroke is a common, potentially life-threatening event that presents both acute and long-term challenges for patients and the healthcare system. The importance of educating patients about key symptoms, rapid diagnosis, and timely therapy is often underestimated. In addition to prevention through the optimal management of risk factors such as high blood pressure and diabetes, early detection of stroke symptoms is crucial. Modern and effective therapies such as thrombolysis and endovascular procedures can significantly improve outcomes if initiated promptly. Familiarity with stroke symptoms is essential for recognizing and differentiating so-called stroke mimics and stroke chameleons. In patients showing corresponding symptoms, immediate referral to a hospital is imperative. The 4-S acronym (Sehstörung, Sprachstörung, Schwäche, schnell handeln - visual disturbance, speech disturbance, weakness, act fast) serves as an easily understandable mnemonic for patients. If stroke is suspected, the emergency services (144) should be contacted immediately, as every minute counts (\"Time is Brain\"). Given that strokes can also present with atypical symptoms, rapid imaging is indispensable in uncertain cases to rule out misdiagnosis. In this context, general practitioners play a crucial role in early detection and timely referral, which again significantly improves the quality of care.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"82 3","pages":"100-104"},"PeriodicalIF":0.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}